Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
Brain and Behavior · 2023
DOI: 10.1002/brb3.2799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2023. Verfasst von Simona Guerzoni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology an…. Hauptthemen laut MEDLINE: Migraine Disorders, Headache Disorders, Secondary. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Galcanezumab is a monoclonal antibody acting against the calcitonin gene‐related peptide approved for the preventive treatment of migraine. The aim of this article is to explore its effectiveness and safety of galcanezumab in chronic migraine (CM) with medication overuse‐headache (MOH).
Methods
Seventy‐eight patients were consecutively enrolled at the Modena headache center and followed up for 15 months. Visits were scheduled every 3 months, and the following variables were collected: the number of migraine days per month (MDM); the painkillers taken per month (PM); the number of days per month in which the patient took, at least, one painkiller; the six‐item headache impact test; and the migraine disability assessment questionnaire (MIDAS) score. Demographic features of the analyzed sample were collected at the baseline and adverse events (AEs) were collected at every visit.
Results
After 12 months, galcanezumab significantly reduced the MDM, the PM, the number of days on medication, the HIT‐6 as well as the MIDAS scores (all p < .0001). The greatest amelioration was obtained in the first trimester of treatment. A higher MDM, a higher NRS score at the baseline, and a higher number of failed preventive treatments negatively predict the CM relief at the year of treatment. No serious AEs were registered and only one drop‐out was due to AE.
Conclusions
Galcanezumab is effective and safe for the treatment of patients affected by CM and MOH. Patients with a higher impairment at the baseline may found less benefits with galcanezumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinic…
- PhD School in Neurosciences, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Post-Gradute School in Pharmacology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Pharmacology Unit, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, Florida, USA.
- VeraSci, Durham, North Carolina, USA.
ORCID-Profile: Carlo Baraldi
Zitieren
APA
Guerzoni, S., Baraldi, C., Castro, F. L., Cainazzo, M. M., & Pani, L. (2023). Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population. Brain and Behavior. https://doi.org/10.1002/brb3.2799
Vancouver
Guerzoni S, Baraldi C, Castro FL, Cainazzo MM, Pani L. Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population. Brain and Behavior. 2023. doi:10.1002/brb3.2799
BibTeX
@article{Guerzoni2023,
author = {Guerzoni, Simona and Baraldi, Carlo and Castro, Flavia Lo and Cainazzo, Maria Michela and Pani, Luca},
title = {Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population},
journal = {Brain and Behavior},
year = {2023},
doi = {10.1002/brb3.2799}
}
EUVIMED